Literature DB >> 29167190

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.

Jonathan P Troost1, Howard Trachtman2, Patrick H Nachman2, Matthias Kretzler2, Cathie Spino2, Radko Komers2, Sarah Tuller2, Kalyani Perumal2, Susan F Massengill2, Elaine S Kamil2, Gia Oh2, David T Selewski2, Patrick Gipson2, Debbie S Gipson1.   

Abstract

BACKGROUND AND OBJECTIVES: Proteinuria is used as an indicator of FSGS disease activity, but its use as a clinical trial end point is not universally accepted. The goal of this study was to refine proteinuria definitions associated with long-term kidney survival. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 466 patients with primary FSGS with proteinuria (urine protein-to-creatinine ratio >1 g/g) were analyzed from five independent cohorts. Proteinuria by months 1, 4, and 8 after study baseline was categorized by conventional definitions of complete (<0.3 g/g) and partial remission (<3.5 g/g and 50% reduction in proteinuria). Novel remission definitions were explored using receiver operating curves. Kaplan-Meier methods were used to estimate the associations of proteinuria with progression to ESRD or a 50% loss in kidney function. Propensity score-adjusted Cox proportional hazards models were used to adjust for baseline proteinuria, eGFR, and therapy.
RESULTS: In the initial derivation cohort, conventional partial remission was not associated with kidney survival. A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77). In the validation cohort analyses, complete remission was associated with better prognosis (6 out of 41 patients progressed to kidney failure; 6.6 per 100 patient-years) as was the novel partial remission (13 out of 71 progressed; 8.5 per 100 patient-years), compared with those with no response (51 out of 116 progressed; 20.1 per 100 patient-years). Conventional partial remission at month 8, but not month 4, was also associated with better response (19 out of 85 patients progressed; risk=10.4 per 100 patient-years). Propensity score-adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002).
CONCLUSIONS: Reaching either a complete or partial remission using a novel or conventional definition was associated with better long-term outcomes in patients with FSGS. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_02_20_CJASNPodcast_18_3_T.mp3.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Cohort Studies; FSGS; Glomerulosclerosis, Focal Segmental; Goals; Humans; Kidney Failure, Chronic; Prognosis; Propensity Score; Proportional Hazards Models; Renal Insufficiency; creatinine; glomerular filtration rate; kidney; proteinuria; surrogate endpoint

Mesh:

Substances:

Year:  2017        PMID: 29167190      PMCID: PMC5967666          DOI: 10.2215/CJN.04780517

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  13 in total

1.  Differential risk of remission and ESRD in childhood FSGS.

Authors:  Debbie S Gipson; Hyunsook Chin; Trevor P Presler; Caroline Jennette; Maria E Ferris; Susan Massengill; Keisha Gibson; David B Thomas
Journal:  Pediatr Nephrol       Date:  2006-01-05       Impact factor: 3.714

2.  Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Authors:  Stéphan Troyanov; Catherine A Wall; Judith A Miller; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2005-02-16       Impact factor: 10.121

3.  Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.

Authors:  Laura H Mariani; Sebastian Martini; Laura Barisoni; Pietro A Canetta; Jonathan P Troost; Jeffrey B Hodgin; Matthew Palmer; Avi Z Rosenberg; Kevin V Lemley; Hui-Ping Chien; Jarcy Zee; Abigail Smith; Gerald B Appel; Howard Trachtman; Stephen M Hewitt; Matthias Kretzler; Serena M Bagnasco
Journal:  Nephrol Dial Transplant       Date:  2018-02-01       Impact factor: 5.992

4.  Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.

Authors:  Sheila Santín; Gemma Bullich; Bárbara Tazón-Vega; Rafael García-Maset; Isabel Giménez; Irene Silva; Patricia Ruíz; José Ballarín; Roser Torra; Elisabet Ars
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 8.237

5.  Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.

Authors:  Aliza Thompson; Daniel C Cattran; Melanie Blank; Patrick H Nachman
Journal:  J Am Soc Nephrol       Date:  2015-06-15       Impact factor: 10.121

Review 6.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.

Authors:  Giuseppe Remuzzi; Ariela Benigni; Andrea Remuzzi
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

7.  Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

Authors:  Andrew S Levey; Daniel Cattran; Aaron Friedman; W Greg Miller; John Sedor; Katherine Tuttle; Bertram Kasiske; Thomas Hostetter
Journal:  Am J Kidney Dis       Date:  2009-07-03       Impact factor: 8.860

8.  Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Authors:  Lesley A Inker; Hasi Mondal; Tom Greene; Taylor Masaschi; Francesco Locatelli; Francesco P Schena; Ritsuko Katafuchi; Gerald B Appel; Bart D Maes; Philip K Li; Manuel Praga; Lucia Del Vecchio; Simeone Andrulli; Carlo Manno; Eduardo Gutierrez; Alex Mercer; Kevin J Carroll; Christopher H Schmid; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2016-03-29       Impact factor: 8.860

9.  Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Authors:  Crystal A Gadegbeku; Debbie S Gipson; Lawrence B Holzman; Akinlolu O Ojo; Peter X K Song; Laura Barisoni; Matthew G Sampson; Jeffrey B Kopp; Kevin V Lemley; Peter J Nelson; Chrysta C Lienczewski; Sharon G Adler; Gerald B Appel; Daniel C Cattran; Michael J Choi; Gabriel Contreras; Katherine M Dell; Fernando C Fervenza; Keisha L Gibson; Larry A Greenbaum; Joel D Hernandez; Stephen M Hewitt; Sangeeta R Hingorani; Michelle Hladunewich; Marie C Hogan; Susan L Hogan; Frederick J Kaskel; John C Lieske; Kevin E C Meyers; Patrick H Nachman; Cynthia C Nast; Alicia M Neu; Heather N Reich; John R Sedor; Christine B Sethna; Howard Trachtman; Katherine R Tuttle; Olga Zhdanova; Gastòn E Zilleruelo; Matthias Kretzler
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

Review 10.  Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.

Authors:  Kyoung Hee Han; Seong Heon Kim
Journal:  Biomed Res Int       Date:  2016-04-18       Impact factor: 3.411

View more
  16 in total

1.  Individualizing Treatment of Steroid-Resistant Nephrotic Syndrome: Registries to the Fore.

Authors:  Arvind Bagga; Aditi Sinha
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

2.  Emerging drugs for treatment of focal segmental glomerulosclerosis.

Authors:  Howard Trachtman
Journal:  Expert Opin Emerg Drugs       Date:  2020-08-12       Impact factor: 4.191

3.  Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.

Authors:  Debbie S Gipson; Michelle A Hladunewich; Richard Lafayette; John R Sedor; Brad H Rovin; Sean J Barbour; Alan McMahon; J Charles Jennette; Patrick H Nachman; Robert N Willette; Marcella Paglione; Feng Gao; Jorge Alfonso Ross Terres; Sue Vallow; M Claire Holland; Kevin S Thorneloe; Dennis L Sprecher
Journal:  Kidney Int Rep       Date:  2020-05-26

4.  DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Authors:  Howard Trachtman; Peter Nelson; Sharon Adler; Kirk N Campbell; Abanti Chaudhuri; Vimal Kumar Derebail; Giovanni Gambaro; Loreto Gesualdo; Debbie S Gipson; Jonathan Hogan; Kenneth Lieberman; Brad Marder; Kevin Edward Meyers; Esmat Mustafa; Jai Radhakrishnan; Tarak Srivastava; Miganush Stepanians; Vladimír Tesar; Olga Zhdanova; Radko Komers
Journal:  J Am Soc Nephrol       Date:  2018-11       Impact factor: 10.121

5.  Amount and selectivity of proteinuria may predict the treatment response in post-transplant recurrence of focal segmental glomerulosclerosis: a single-center retrospective study.

Authors:  Hideki Ban; Kenichiro Miura; Naoto Kaneko; Yoko Shirai; Tomoo Yabuuchi; Kiyonobu Ishizuka; Hiroko Chikamoto; Yuko Akioka; Satoru Shimizu; Hideki Ishida; Kazunari Tanabe; Motoshi Hattori
Journal:  Pediatr Nephrol       Date:  2021-02-04       Impact factor: 3.714

6.  Short term outcome of patients attending a renal-immunology clinic in central India.

Authors:  M Atlani; N K Kapoor; D Joshi; R Sutar; T Sharma; A Joshi
Journal:  J Postgrad Med       Date:  2022 Apr-Jun       Impact factor: 1.566

7.  Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.

Authors:  Radko Komers; Ulysses Diva; Jula K Inrig; Andrea Loewen; Howard Trachtman; William E Rote
Journal:  Kidney Int Rep       Date:  2020-01-08

8.  Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome.

Authors:  Debbie S Gipson; Howard Trachtman; Anne Waldo; Keisha L Gibson; Sean Eddy; Katherine M Dell; Tarak Srivastava; Kevin V Lemley; Larry A Greenbaum; Sangeeta Hingorani; Kevin E Meyers; Frederick J Kaskel; Kimberly J Reidy; Christine B Sethna; Cheryl L Tran; Chia-Shi Wang; Katherine R Tuttle; Gia Oh; Alicia M Neu; Elizabeth Brown; Jen-Jar Lin; Jennifer Lai Yee; Therese M Roth; Jonathan P Troost; Brenda W Gillespie; Matthew G Sampson; Matthias Kretzler; Wenjun Ju
Journal:  Kidney Int Rep       Date:  2019-12-05

9.  Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis.

Authors:  Yan-Cheng Chao; Howard Trachtman; Debbie S Gipson; Cathie Spino; Thomas M Braun; Kelley M Kidwell
Journal:  Contemp Clin Trials       Date:  2020-03-19       Impact factor: 2.226

10.  Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.

Authors:  Jonathan P Troost; Howard Trachtman; Cathie Spino; Frederick J Kaskel; Aaron Friedman; Marva M Moxey-Mims; Richard N Fine; Jennifer J Gassman; Jeffrey B Kopp; Liron Walsh; Rong Wang; Debbie S Gipson
Journal:  Am J Kidney Dis       Date:  2020-08-10       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.